Remedy and UC Berkeley launch wellness platform

Share this article:

Remedy Health Media is partnering with the University of California-Berkeley on, which will deliver wellness information to consumers with the customary interactive spoonfuls of sugar—quizzes, slideshows, email alerts and social media feeds, along with roundtables and video chats featuring Berkeley experts.

Remedy and the Berkeley editorial board will collaborate on content, said Remedy. The site is expected to draw upwards of 1.25 million monthly unique visitors during its first quarter, the company said.

The site will be supported by advertising—inaugural advertisers include ProCure Proton Therapy Centers—pending approval of advertisers by a Berkeley review board, which the partners see as a differentiating point. It's in “very early beta” yet, said a Remedy spokesperson, but the aim is to establish a “device-agnostic platform” that engages proactive wellness info-seekers.

“We think wellness and prevention are going to become more important, and we're really excited about doing more on that side,” said CEO Michael Cunnion.

Remedy Health Media acquired HealthCentral in 2011 and last month launched Patient Health Services, a platform which allows docs to push condition-appropriate health and wellness information to patients.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in News

New lipid agents are high on potency, low on doc awareness

New lipid agents are high on potency, low ...

The new PCSK9 class of cholesterol-lowering antibodies continues to look promising, but many doctors—particularly PCPs—have never even heard of the experimental drugs.

Novartis may have game-changing drug

Novartis may have game-changing drug

Key opinion leaders indicate they are ready to embrace Novartis's experimental heart failure medication LCZ696. Such a move could upend heart failure treatment protocols.

Five things for pharma marketers to know: Tuesday, September 2

Five things for pharma marketers to know: Tuesday, ...

Sanofi and Regeneron unveil Phase-III results of their PCSK9; Merck will present data on its anti-PD-1 at the end of this month; WSJ op/ed suggests US should lead fight against ...